Literature DB >> 33607163

Comparison of memory, affective behavior, and neuropathology in APPNLGF knock-in mice to 5xFAD and APP/PS1 mice.

Andrea Locci1, Hector Orellana1, Guadalupe Rodriguez1, Meredith Gottliebson1, Bryan McClarty1, Sky Dominguez1, Rachel Keszycki1, Hongxin Dong2.   

Abstract

Transgenic mouse models of Aβ amyloidosis generated by knock-in of a humanized Aβ sequence can offer some advantages over the transgenic models that overexpress amyloid precursor protein (APP). However, systematic comparison of memory, behavioral, and neuropathological phenotypes between these models has not been well documented. In this study, we compared memory and affective behavior in APPNLGF mice, an APP knock-in model, to two widely used mouse models of Alzheimer's disease, 5xFAD and APP/PS1 mice, at 10 months of age. We found that, despite similar deficits in working memory, object recognition, and social recognition memory, APPNLGF and 5xFAD mice but not APP/PS1 mice show compelling anxiety- and depressive-like behavior, and exhibited a marked impairment of social interaction. We quantified corticolimbic Aβ plaques, which were lowest in APPNLGF, intermediate in APP/PS1, and highest in 5xFAD mice. Interestingly, analysis of plaque size revealed that plaques were largest in APP/PS1 mice, intermediate in 5xFAD mice, and smallest in APPNLGF mice. Finally, we observed a significantly higher percentage of the area occupied by plaques in both 5xFAD and APP/PS1 relative to APPNLGF mice. Overall, our findings suggest that the severity of Aβ neuropathology is not directly correlated with memory and affective behavior impairments between these three transgenic mouse models. Additionally, APPNLGF may represent a valid mouse model for studying AD comorbid with anxiety and depression. Published by Elsevier B.V.

Entities:  

Keywords:  APP(NLGF); Affective behavior; Alzheimer’s disease; Aβ plaques; Memory; Mouse model

Mesh:

Substances:

Year:  2021        PMID: 33607163      PMCID: PMC7980131          DOI: 10.1016/j.bbr.2021.113192

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.352


  84 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

2.  Longitudinal behavioral changes in the APP/PS1 transgenic Alzheimer's disease model.

Authors:  Sherry A Ferguson; Sumit Sarkar; Larry C Schmued
Journal:  Behav Brain Res       Date:  2013-01-04       Impact factor: 3.332

3.  The locus coeruleus neuroprotective drug vindeburnol normalizes behavior in the 5xFAD transgenic mouse model of Alzheimer's disease.

Authors:  David Braun; Douglas L Feinstein
Journal:  Brain Res       Date:  2017-12-21       Impact factor: 3.252

Review 4.  Searching for new animal models of Alzheimer's disease.

Authors:  Roberta Epis; Fabrizio Gardoni; Elena Marcello; Armando Genazzani; Pier Luigi Canonico; Monica Di Luca
Journal:  Eur J Pharmacol       Date:  2009-10-15       Impact factor: 4.432

5.  Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD.

Authors:  M N Sabbagh; K Cooper; J DeLange; J D Stoehr; K Thind; T Lahti; B Reisberg; L Sue; L Vedders; S R Fleming; T G Beach
Journal:  Curr Alzheimer Res       Date:  2010-06       Impact factor: 3.498

6.  Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease.

Authors:  Oliver Ambrée; Helene Richter; Norbert Sachser; Lars Lewejohann; Ekrem Dere; Maria Angelica de Souza Silva; Arne Herring; Kathy Keyvani; Werner Paulus; Wolf-Rüdiger Schäbitz
Journal:  Neurobiol Aging       Date:  2008-02-20       Impact factor: 4.673

7.  Reduction in open field activity in the absence of memory deficits in the AppNL-G-F knock-in mouse model of Alzheimer's disease.

Authors:  Lauren S Whyte; Kim M Hemsley; Adeline A Lau; Sofia Hassiotis; Takashi Saito; Takaomi C Saido; John J Hopwood; Timothy J Sargeant
Journal:  Behav Brain Res       Date:  2017-09-05       Impact factor: 3.332

8.  Cognitive deficits in single App knock-in mouse models.

Authors:  Akira Masuda; Yuki Kobayashi; Naomi Kogo; Takashi Saito; Takaomi C Saido; Shigeyoshi Itohara
Journal:  Neurobiol Learn Mem       Date:  2016-07-01       Impact factor: 2.877

9.  TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting β-amyloidosis in 5XFAD mice.

Authors:  L Devi; M Ohno
Journal:  Transl Psychiatry       Date:  2015-05-05       Impact factor: 6.222

10.  Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis.

Authors:  Yasufumi Sakakibara; Michiko Sekiya; Takashi Saito; Takaomi C Saido; Koichi M Iijima
Journal:  BMC Neurosci       Date:  2018-07-28       Impact factor: 3.288

View more
  2 in total

1.  Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer's disease.

Authors:  Stefania Forner; Shimako Kawauchi; Gabriela Balderrama-Gutierrez; Enikö A Kramár; Dina P Matheos; Jimmy Phan; Dominic I Javonillo; Kristine M Tran; Edna Hingco; Celia da Cunha; Narges Rezaie; Joshua A Alcantara; David Baglietto-Vargas; Camden Jansen; Jonathan Neumann; Marcelo A Wood; Grant R MacGregor; Ali Mortazavi; Andrea J Tenner; Frank M LaFerla; Kim N Green
Journal:  Sci Data       Date:  2021-10-15       Impact factor: 6.444

2.  Dramatic impacts on brain pathology, anxiety, and cognitive function in the knock-in APPNL-G-F mouse model of Alzheimer disease following long-term voluntary exercise.

Authors:  Majid H Mohajerani; Robert J McDonald; Jogender Mehla; Scott H Deibel; Hadil Karem; Shakhawat Hossain; Sean G Lacoursiere; Robert J Sutherland
Journal:  Alzheimers Res Ther       Date:  2022-09-30       Impact factor: 8.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.